Abstract
The management of Crohn’s disease (CD) using anti-tumour necrosis factor therapy in tuberculosis (TB)-endemic regions poses major clinical challenges due to the risk of latent TB infection reactivation. This bibliometric–systematic literature review synthesised evidence from 17 peer-reviewed studies (2020–2025) evaluating adalimumab administered with concurrent prophylactic antitubercular therapy. Thematic synthesis and bibliometric mapping using VOSviewer demonstrated that adalimumab achieved 60–85% clinical remission in moderate-to-severe CD and axial spondyloarthritis while enhancing mucosal healing. However, 1–3% of patients developed active TB despite appropriate screening and isoniazid prophylaxis, revealing false-negative diagnostics and partial chemoprophylaxis protection. These findings highlight the need for region-specific frameworks integrating multimodal screening, targeted prophylaxis and ongoing clinical surveillance. Adalimumab remains a cornerstone biologic in TB-endemic settings, but its safe use requires adaptive, context-driven protocols emphasising vigilant risk mitigation.
Article Type
Review
Publication Date
2-21-2026
First Page
171
Last Page
183
Creative Commons License
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 International License.
Recommended Citation
Shofa, Nyimas Maida; Mudjari, Nurike Setiyari; Ekawati, Rusdiyana; Arianti, Arianti; Mufida, Annisa Zahra; Widodo, Budi; and Sugihartono, Titong
(2026)
"Adalimumab Therapy for Crohn’s Disease and Axial Spondyloarthritis in Latent Tuberculosis: A bibliometric-systematic literature review,"
Sultan Qaboos University Medical Journal: Vol. 26: 171-183.
DOI: https://doi.org/10.18295/2075-0528.2971
